SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders and rare diseases, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received official notification from Nasdaq on July 18, 2025, confirming that its shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days, satisfying Listing Rule 5550(a)(2).
With this achievement, Nasdaq has closed the previous bid price deficiency matter, marking an important milestone for SciSparc's continued listing on the exchange.
SciSparc Ltd. (Nasdaq: SPRC), una societ脿 farmaceutica in fase clinica focalizzata sui disturbi del sistema nervoso centrale e sulle malattie rare, ha riconquistato con successo la conformit脿 al requisito minimo del prezzo di offerta di Nasdaq. La societ脿 ha ricevuto la notifica ufficiale da Nasdaq il 18 luglio 2025, confermando che le sue azioni hanno mantenuto un prezzo di chiusura di offerta di almeno $1,00 per 10 giorni lavorativi consecutivi, soddisfacendo la Regola di Quotazione 5550(a)(2).
Con questo risultato, Nasdaq ha chiuso la questione relativa alla precedente carenza del prezzo di offerta, segnando un traguardo importante per la continuazione della quotazione di SciSparc sull鈥檈xchange.
SciSparc Ltd. (Nasdaq: SPRC), una compa帽铆a farmac茅utica en etapa cl铆nica enfocada en trastornos del sistema nervioso central y enfermedades raras, ha recuperado con 茅xito el cumplimiento del requisito m铆nimo del precio de oferta de Nasdaq. La empresa recibi贸 una notificaci贸n oficial de Nasdaq el 18 de julio de 2025, confirmando que sus acciones mantuvieron un precio de cierre de oferta de $1.00 o m谩s durante 10 d铆as h谩biles consecutivos, cumpliendo con la Regla de Listado 5550(a)(2).
Con este logro, Nasdaq ha cerrado el asunto previo relacionado con la deficiencia en el precio de oferta, marcando un hito importante para la continuidad de la cotizaci贸n de SciSparc en la bolsa.
SciSparc Ltd. (Nasdaq: SPRC)電� 欷戩稊鞁犼步瓿� 歆堩櫂 氚� 頋穩歆堩櫂鞐� 歆戩頃橂姅 鞛勳儊 雼硠 鞝滌暯須岇偓搿�, 雮橃姢雼レ潣 斓滌唽 鞛呾鞍 臧�瓴� 鞖旉贝鞚� 靹标车鞝侅溂搿� 於╈”頃橃榾鞀惦媹雼�. 須岇偓電� 2025雲� 7鞗� 18鞚� 雮橃姢雼レ溂搿滊秬韯� 瓿奠嫕 韱奠毳� 氚涭晿鞙茧┌, 欤检嫕鞚� 10瓯半灅鞚� 鞐办啀鞙茧 $1.00 鞚挫儊 膦呹皜毳� 鞙犾頃橃棳 靸侅灔 攴滌箼 5550(a)(2)毳� 於╈”頄堨潓鞚� 頇曥澑氚涭晿鞀惦媹雼�.
鞚措矆 靹标臣搿� 雮橃姢雼レ潃 鞚挫爠 鞛呾鞍 臧�瓴� 攵�臁� 氍胳牅毳� 膦呹舶頃橃榾鞙茧┌, SciSparc鞚� 瓯半灅靻� 靸侅灔 歆�靻嶌棎 欷戩殧頃� 鞚挫爼響滉皜 霅橃棃鞀惦媹雼�.
SciSparc Ltd. (Nasdaq : SPRC), une soci茅t茅 pharmaceutique en phase clinique sp茅cialis茅e dans les troubles du syst猫me nerveux central et les maladies rares, a r茅ussi 脿 se conformer 脿 nouveau 脿 l'exigence minimale du prix d'offre de Nasdaq. La soci茅t茅 a re莽u une notification officielle de Nasdaq le 18 juillet 2025, confirmant que ses actions ont maintenu un prix de cl么ture d'offre de 1,00 $ ou plus pendant 10 jours ouvrables cons茅cutifs, satisfaisant ainsi 脿 la r猫gle de cotation 5550(a)(2).
Gr芒ce 脿 cette r茅ussite, Nasdaq a clos le dossier relatif 脿 la pr茅c茅dente insuffisance du prix d'offre, marquant une 茅tape importante pour la poursuite de la cotation de SciSparc sur la bourse.
SciSparc Ltd. (Nasdaq: SPRC), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Erkrankungen des zentralen Nervensystems und seltenen Krankheiten, hat die Einhaltung der Mindestgebotspreisanforderung der Nasdaq erfolgreich wiedererlangt. Das Unternehmen erhielt am 18. Juli 2025 eine offizielle Benachrichtigung von der Nasdaq, die best盲tigte, dass die Aktien an 10 aufeinanderfolgenden Handelstagen einen Schlussgebotspreis von mindestens $1,00 gehalten haben und somit die Notierungsregel 5550(a)(2) erf眉llt ist.
Mit diesem Erfolg hat Nasdaq die vorherige Problematik bez眉glich des Gebotspreises abgeschlossen, was einen wichtigen Meilenstein f眉r die weitere Notierung von SciSparc an der B枚rse darstellt.
- Regained Nasdaq listing compliance, removing delisting risk
- Maintained share price above $1.00 for 10 consecutive trading days
- Resolved previous bid price deficiency matter with Nasdaq
- Previous trading below minimum bid price requirement indicates historical stock price weakness
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (鈥淪ciSparc鈥� or the 鈥淐ompany鈥�) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reported the receipt on July 18, 2025 of a written notice from The Nasdaq Stock Market LLC (鈥淣asdaq鈥�) indicating that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company鈥檚 ordinary shares to maintain a minimum bid price of
The Nasdaq staff made this determination of compliance after the closing bid price of the Company鈥檚 ordinary shares was at
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc鈥檚 focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds鈥� oil-based products on the听Marketplace.
Investor Contact:
Tel: +972-3-6167055
FAQ
Has SciSparc (SPRC) regained Nasdaq compliance in 2025?
What is the minimum bid price requirement for Nasdaq listing that SPRC had to meet?
What does SciSparc's Nasdaq compliance mean for investors?
What is SciSparc's main business focus?
